Article
RVD With Weekly Bortezomib Has a Favorable Toxicity and Effectiveness Profile in a Large Cohort of US Veterans With Multiple Myeloma
- Author:
- Maxwell M. Krem, MD, PhD
- June K. Corrigan, MS
- Sarvari Yellapragada, MD
- Joseph G. Bennett, MD
- Nhan V. Do, MD
- Mary T. Brophy, MD
- Nikhil C. Munshi, MD
- Daphne R. Friedman, MD
- Nathanel R. Fillmore, PhD